NASHUA, N.H., April 8, 2016, iCAD, Inc., (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the identification and treatment of cancer, today announced that its mammography Computer Aided Detection (CAD) solution is now available on Fujifilm’s Aspire Cristalle full field digital mammography system.

“iCAD is pleased to provide our leading mammography CAD solution to Fujifilm’s Aspire Cristalle customers worldwide.  We trust our integrated solutions will now provide radiologists with a clinical decision support tool designed to help provide the highest quality  care for mammography patients”, said Diane Clifford, director of marketing for cancer detection solutions at iCAD.

The PowerLook Advanced Mammography Platform is a flexible solution supporting iCAD’s industry leading computer-aided detection algorithm for digital mammography that assists radiologists in the detection of breast cancer.  The iCAD solution is used by more than 3,000 mammography facilities worldwide.

“Fujifilm is happy to have reached this important milestone with iCAD, moving our customers another important step forward with the ability to simplify the reading of digital mammography exams” said Rob Fabrizio, director of marketing and product development at FUJIFILM Medical Systems U.S.A., Inc. “We trust our customers will be pleased with this coupling of the most requested CAD platform with the exceptional imaging capabilities of our Aspire Cristalle mammography system.”

Fujifilm is constantly working to develop the most advanced digital mammography systems, to assist in the early detection of breast cancer. Aspire Cristalle brings together Fujifilm’s extensive research, expertise and experience. The unique platform allows easy upgradability to future technologies, while offering optimal imaging of all breast types at lower dose.  The Aspire Cristalle will be on display at the National Consortium of Breast Centers (NCoBC) conference from April 9-13, 2016 in Las Vegas, NV.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or or

About Fujifilm

FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of diagnostic imaging products and medical informatics solutions to meet the needs of healthcare facilities today and well into the future. From an unrivaled selection of digital x-ray systems, to the Synapse® brand of PACS, RIS and cardiovascular products, to advanced women’s health imaging systems, Fujifilm has products that are ideal for any size imaging environment. The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. supplies high quality, technologically advanced endoscopes to the medical market. The TeraMedica Division delivers healthcare informatics, and is the leading provider of vendor neutral, enterprise-wide solutions for unrestricted medical image management. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Stamford, CT. For more information please visit and

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies.  In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit:


Berry & Company Public Relations, LLC
Lynn Granito

Lauren Geloso
(914) 789-8303